Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis

References

• Seaman CD, Xavier F, Ragni MV. Hemophilia A (factor VIII deficiency). Hematol Oncol Clin North Am. 2021;35(6):1117–1129. doi: 10.1016/j.hoc.2021.07.006
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia Internet. 2020 [[cited 2022 Aug 1]];26:1–158. doi: 10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Bidlingmaier C, Mahlangu JN, et al. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost Internet. 2018 [[cited 2023 May 13]];16(10):2106–2110. doi: 10.1111/jth.14257
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost Internet. 2014 [[cited 2022 Aug 12]];12(11):1935–1939. doi: 10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• Olasupo OO, Lowe MS, Krishan A, et al. Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia a or B. Cochrane Database Of Systematic Reviews [Internet]. 2021;2021(8). doi: 10.1002/14651858.CD014201
   Google Scholar
• Chai-Adisaksopha C, Hillis C, Thabane L, et al. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia Internet. 2015 [[cited 2022 Aug 7]];21(6):731–735. doi: 10.1111/hae.12750
   PubMed Web of Science ®Google Scholar
• Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood Internet. 2014 [[cited 2022 Nov 16]];124(23):3365–3372. doi: 10.1182/blood-2014-05-577643
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects. Blood Internet. 2016 [[cited 2022 Aug 9]];127(13):1633–1641. doi: 10.1182/blood-2015-06-650226
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9):809–818. doi: 10.1056/NEJMoa1703068
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia a with inhibitors. Blood Internet. 2019;134(24):2127–2138. doi: 10.1182/blood.2019001869
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med Internet. 2018;379(9):811–822. doi: 10.1056/NEJMoa1803550
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia a (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol Internet. 2019;6(6):e295–e305. doi: 10.1016/S2352-3026(19)30054-7
   PubMed Web of Science ®Google Scholar
• Yang R, Wang S, Wang X, et al. Prophylactic emicizumab for hemophilia a in the Asia‐Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost Internet. 2022;6:e12670. doi: 10.1002/rth2.12670
   PubMed Web of Science ®Google Scholar
• Négrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia a (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol Internet. 2023;10:e168–e177. doi: 10.1016/S2352-3026(22)00377-5
   PubMed Web of Science ®Google Scholar
• Misgav M, Brutman‐Barazani T, Budnik I, et al. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data. Haemophilia Internet. 2021;27(2):253–260. doi: 10.1111/hae.14261
   PubMed Web of Science ®Google Scholar
• Zharkov PА, Voronin KA, Andreeva TA, et al. Bleeding rate reduction in children with hemophilia a and inhibitors treated with emicizumab in the real-world clinical setting. Pediatr Hematol Immunopathol Internet. 2022;21(1):66–71. doi: 10.24287/1726-1708-2022-21-1-66-71
   Google Scholar
• Glonnegger H, Andresen F, Kapp F, et al. Emicizumab in children: bleeding episodes and outcome before and after transition to emicizumab. BMC Pediatr Internet. 2022;22(1):487. doi: 10.1186/s12887-022-03546-1
   PubMed Web of Science ®Google Scholar
• Batt K, Schultz BG, Caicedo J, et al. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia a switching from FVIII prophylaxis to emicizumab. Current Medical Research And Opinion Internet. 2022;38(10):1685–1693. doi: 10.1080/03007995.2022.2105072
   PubMed Web of Science ®Google Scholar
• Liu G, Huang K, Li G, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China. Front Pediatr Internet. 2022;10:1–7. doi: 10.3389/fped.2022.992267
   Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ Internet. 2021:n160. doi: 10.1136/bmj.n160
   PubMedGoogle Scholar
• Higging J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022) [Internet]. Cochrane; 2022. www.training.cochrane.org/handbook
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data published by. International Biometric Society Stable https://www.jstor.org/stable/2529310.1977;33:159–174.
   Google Scholar
• Rohatgi A WebPlotdigitizer [Internet]. Pacifica (CA USA); 2022. https://automeris.io/WebPlotDigitizer
   Google Scholar
• van Balen EC, O’Mahony B, Cnossen MH, et al. Patient‐relevant health outcomes for hemophilia care: development of an international standard outcomes set. Res Pract Thromb Haemost Internet. 2021;5(4):e12488. https://linkinghub.elsevier.com/retrieve/pii/S2475037922013681
   PubMed Web of Science ®Google Scholar
• Chen Y, Cheng SJ, Thornhill T, et al. Health care costs and resource use of managing hemophilia A: a targeted literature review. J Manag Care Spec Pharm Internet. 2023;29(6):647–658. doi: 10.18553/jmcp.2023.29.6.647
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ Internet. 2016;355:i4919. https://www.bmj.com/lookup/doi/10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction — GRADE evidence profiles and summary of findings tables. J Clin Epidemiol Internet. 2011 [[cited 2023 Apr 30]];64(4):383–394.doi: 10.1016/j.jclinepi.2010.04.026
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII–mimetic function of humanized bispecific antibody in hemophilia a. N Engl J Med Internet. 2016;374(21):2044–2053. doi: 10.1056/NEJMoa1511769
   PubMed Web of Science ®Google Scholar
• Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia a without inhibitors. Haemophilia. 2019;25(6):979–987. doi: 10.1111/hae.13848
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia a with inhibitors: HAVEN 1 study. Haemophilia Internet. 2019;25(1):33–44. doi: 10.1111/hae.13618
   PubMed Web of Science ®Google Scholar
• Skinner MW, Négrier C, Paz‐Priel I, et al. The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia a without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia Internet. 2021;27(5):854–865. doi: 10.1111/hae.14363
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Kessler CM, Germini F, et al. Bleeding events in people with congenital haemophilia a without factor VIII inhibitors receiving prophylactic factor VIII treatment: a systematic literature review. Haemophilia Internet. 2023 [[cited 2023 Jul 10]];29(4):954–962. doi: 10.1111/hae.14803
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Nevitt SJ, Simpson ML, et al. Bypassing agent prophylaxis in people with hemophilia a or B with inhibitors. Cochrane Database Syst Rev Internet. 2017 [cited 2023 Jul 10];2020(3): doi: 10.1002/14651858.CD011441.pub2
   Google Scholar
• López-Fernández MF, Roca CA, Álvarez-Román MT, et al. Spanish consensus guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost Internet. 2016;115(5):872–895. doi: 10.1160/TH15-07-0568
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity) identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the func. PLoS One Internet. 2013 [[cited 2022 Oct 4]];8(2):57479.doi: 10.1371/journal.pone.0057479
   PubMed Web of Science ®Google Scholar
• Euser AM, Zoccali C, Jager KJ, et al. Cohort studies: prospective versus retrospective. Nephron Clin Pract Internet. 2009 [[cited 2023 Jul 10]];113(3):c214–c217.doi: 10.1159/000235241
   PubMedGoogle Scholar
• Fischer K, Poonnoose P, Dunn AL, et al. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia Internet. 2017;23(1):11–24. doi: 10.1111/hae.13088
   PubMed Web of Science ®Google Scholar
• Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia a. Haemophilia Internet. 2014 [[cited 2023 Jul 10]];20(5):607–615. doi: 10.1111/hae.12438
   PubMed Web of Science ®Google Scholar
• Hartmann R, Feenstra T, Valentino L, et al. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018;16(8):1580–1591. doi: 10.1111/jth.14203
   Web of Science ®Google Scholar
• Aledort LM. Deaths associated with emicizumab in patients with hemophilia a. N Engl J Med Internet. 2019 [[cited 2023 May 4]];381(19):1878–1879. doi: 10.1056/NEJMc1909742
   PubMed Web of Science ®Google Scholar
• Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost. 2019;17(8):1269–1272. doi: 10.1111/jth.14556
   PubMed Web of Science ®Google Scholar
• Linari S, Castaman G. Concomitant use of rFviia and emicizumab in people with hemophilia a with inhibitors: Current perspectives and emerging clinical evidence. Ther Clin Risk Manag Internet. 2020;16:461–469. https://www.dovepress.com/concomitant-use-of-rfviia-and-emicizumab-in-people-with-hemophilia-a-w-peer-reviewed-article-TCRM
   PubMed Web of Science ®Google Scholar
• Kizilocak H, Marquez-Casas E, Malvar J, et al. Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia a patients on emicizumab. Haemophilia Internet. 2023;29(1):100–105. doi: 10.1111/hae.14684
   PubMedGoogle Scholar
• Gundabolu K, Goldsweig A, Bhatt VR, et al. ST‐Segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia a patient receiving emicizumab and recombinant activated factor VII. Haemophilia Internet. 2020;26(1). doi: 10.1111/hae.13871
   PubMed Web of Science ®Google Scholar
• Maria A, Alessandro C, Declan N, et al. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. J Thromb Haemost. 2023;21(3):546–552. doi: 10.1016/j.jtha.2023.01.010
   PubMed Web of Science ®Google Scholar
• Schmitt C, Emrich T, Chebon S, et al. Low immunogenicity of emicizumab in persons with haemophilia a. Haemophilia Internet. 2021;27(6):984–992. doi: 10.1111/hae.14398
   PubMed Web of Science ®Google Scholar
• Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:1–9. doi: 10.1136/bmj.j4008
   Google Scholar
• Gogia P, Tarantino M, Schramm W, et al. New directions to develop therapies for people with hemophilia. Expert Rev Hematol Internet. 2023;16(6):417–433. doi: 10.1080/17474086.2023.2184341
   PubMed Web of Science ®Google Scholar
• Blair HA. Emicizumab : A Review in Haemophilia A. Drugs Internet. 2019;79(15):1697–1707. doi: 10.1007/s40265-019-01200-2
   PubMed Web of Science ®Google Scholar
• Teranishi Y, Soeda T, Koga H, et al. New factor VIII function-mimetic bispecific antibodies engineered from emicizumab for further improving the treatment of hemophilia a. Res Pract Thromb Haemost Internet. 2020;4:579 [[cited 2023 Jun 6]]. Available from: https://abstracts.isth.org/abstract/new-factor-viii-function-mimetic-bispecific-antibodies-engineered-from-emicizumab-for-further-improving-the-treatment-of-hemophilia-a/
   Google Scholar
• Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia a mice. 2021 [cited 2023 Jun 5]. Available from: http://ashpublications.org/blood/article-pdf/138/14/1258/1827162/bloodbld2020010331.pdf
   Google Scholar